For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Neomycin Sulphate, Polymyxin B Sulfate and Bacitracin Zinc Powder

Similar documents
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BETNESOL - N

CORTISPORIN Ointment (neomycin and polymyxin B sulfates, bacitracin zinc, and. hydrocortisone ointment, USP)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM. Oxiconazole Nitrate Cream

AUSTRALIAN PRODUCT INFORMATION SOFRADEX (FRAMYCETIN SULFATE, GRAMICIDIN AND DEXAMETHASONE (AS SODIUM METASULFOBENZOATE))

NEOSPORIN G.U. Irrigant Sterile (neomycin sulfate polymyxin B sulfate solution for irrigation)

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)

For a full list of excipients, see section 6.1. A sterile, clear, bright, colourless, aqueous solution.

NEW ZEALAND DATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory COBADEX SYRUP

POLIORIX. Poliomyelitis Vaccine (Inactivated) IP. Inactivated Polio Virus Type 3 (Saukett strain)

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory. Light Liquid Paraffin and White Soft Paraffin Cream

SUMMARY OF PRODUCT CHARACTERISTICS

CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)

Health Products Regulatory Authority

NEW ZEALAND DATA SHEET

PRESCRIBING INFORMATION. BaciJect. Bacitracin for injection U.S.P. Powder for Solution. 50,000 Units/Vial. Antibiotic

PRESCRIBING INFORMATION

DOSAGE AND ADMINISTRATION

ROSOBAC-1GM / ROSOBAC-FORT

Coly-Mycin S Otic with Neomycin and Hydrocortisone (colistin sulfate neomycin sulfate thonzonium bromide hydrocortisone acetate otic suspension)

Aciphin Ceftriaxone Sodium

SUMMARY OF PRODUCT CHARACTERISTICS

2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 5.631g fosfomycin trometamol equivalent to 3.0 g fosfomycin.

Summary of Product Characteristics

PRESCRIBING INFORMATION. Otic Solution. Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution USP. Ophthalmic Ointment

CAUTION Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

AXITAB-CV TAB. COMPOSITION :

SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT. Lamisil 1% cutaneous solution. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Package Insert. Constipeg

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS. Cefuroxime Axetil Tablets IP 125/250/500mg

SUMMARY OF THE PRODUCT CHARACTERISTICS. The content of electrolyte ions per sachet when made up to 125 ml of solution.

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory GRISOVIN- FP. Griseofulvin Tablets I.P.

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory EUMOSONE. Clobetasone Cream IP

Package Insert. Elkar

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

PRODUCT INFORMATION. Colistin Link. Colistin 150 mg/2 ml (as colistimethate sodium) powder for injection vial

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFSPAN DT 100 / CEFSPANORAL SUSPENSION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Mencevax ACWY. 1 Name of the medicinal product Mencevax ACWY.

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

Summary of product characteristics (SmPC)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

ALTARGO TM Retapamulin. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w)

M0BCore Safety Profile

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory VIBELAN FORTE. Nicotinamide IP

AMPICLOX TM Ampicillin-cloxacillin

GlaxoSmithKline. Renal impairment. Hepatic impairment

SUMMARY OF PRODUCT CHARACTERISTICS

PRESCRIBING INFORMATION PRODUCT MONOGRAPH HUMATIN*CAP

PRESCRIBING INFORMATION Including Patient Medication Information. Colistimethate for Injection USP (colistimethate sodium)

SUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion

AUSTRALIAN PRODUCT INFORMATION RESOLVE PLUS 1.0 (MICONAZOLE NITRATE, HYDROCORTISONE) CREAM

VANLID Capsules (Vancomycin hydrochloride)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:

Vancomycin Orion , Version 2 Public Summary of the Risk Management Plan

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Package Insert. D-Bright

Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection)

SUMMARY OF PRODUCT CHARACTERISTICS

100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L., folium) ( 4-8:1). Extraction solvent: ethanol 30% (m/m).

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 40 g/l is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin.

ALTARGO. Retapamulin. Retapamulin 10 mg per gram (1% w/w)

DOSAGE FORMS AND STRENGTHS Cream: Each gram contains 10 mg of ozenoxacin (1%) (3).

This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccinations.

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory TENOVATE M. Clobetasol Propionate and Miconazole Nitrate Skin Cream

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

TOUGH ON IMPETIGO GENTLE ON THE1 PATIENT. Demonstrated efficacy and safety1. New treatment option now available!

APPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS

New Zealand Data Sheet COLISTIN-LINK

Excipients with known effect: Each gramme of gel contains 1 mg methyl parahydroxybenzoate (E-218) and 0.5 mg propyl parahydroxybenzoate (E-216).

INDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

SUMMARY OF PRODUCT CHARACTERISTICS

Colistimethate sodium for injection and inhalation COLISTIN COMPOSITION

Summary of Product Characteristics Updated 01-May-2015 Meda Pharmaceuticals

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Package Insert. Cognitin

D90 (27/10/2005) Final SmPC NL/H/653/01

2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each capsule contains PARACETAMOL 500mg For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM Solution for infusion. A clear, slightly viscous liquid; it is almost colourless, yellow, amber or green.

HIDROKORTIZON SA HLORAMFENIKOLOM (10 mg + 2 mg) / ml, eye drops, suspension

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

Core Safety Profile. Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% SK/H/PSUR/0005/001 Date of FAR:

Transcription:

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN ANTIBIOTIC POWDER Neomycin Sulphate, Polymyxin B Sulfate and Bacitracin Zinc Powder QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains: Polymyxin B Sulfate USP equivalent to Polymyxin B 5000 units Bacitracin Zinc IP equivalent to Bacitracin 400 units Neomycin Sulphate IP equivalent to Neomycin 3400 units PHARMACEUTICAL FORM Powder for topical use. CLINICAL PARTICULARS Therapeutic Indications NEOSPORIN ANTIBIOTIC POWDER is indicated in conditions where superficial bacterial skin infection is present or likely to occur. These include: Prophylaxis in graft donor sites, the suturing of lacerations, accidental cuts, scratches and abrasions. Treatment of infected ulcers, accidental cuts, scratches and abrasions and superficial skin infections following surgical procedures and minor burns, impetigo and secondarily infected skin conditions. The use of NEOSPORIN ANTIBIOTIC POWDER does not exclude concomitant systemic therapy with antibiotics where appropriate (see Special Warnings and Special Precautions for Use). Posology and Method of Administration Topical powder: NEOSPORIN ANTIBIOTIC POWDER is for topical skin administration only. Populations Adults Following any necessary removal of debris, such as pus, crusts, etc. from the affected area, a thin layer of powder should be applied one to three times daily, depending on the clinical condition. 1

Treatment should not be continued for more than seven days without medical supervision. Children NEOSPORIN ANTIBIOTIC POWDER is suitable for use in children (two years and over) at the same dose as adults. A possibility of increased absorption exists in very young children, thus the product is not recommended for use in neonates and infants (less than two years) (see Contraindications and Special Warnings and Special Precautions for Use). Elderly NEOSPORIN ANTIBIOTIC POWDER is suitable for use in the elderly. Caution should be exercised in cases where a decrease in renal function exists and significant systemic absorption of neomycin sulphate may occur (see Special Warnings and Special Precautions for Use). Renal Impairment Dosage should be reduced in patients with reduced renal function (see Special Warnings and Special Precautions for Use). Contraindications The use of NEOSPORIN ANTIBIOTIC POWDER is contraindicated in patients who have demonstrated allergic hypersensitivity to any of the ingredients of the product or to crosssensitising substances such as framycetin, kanamycin, gentamycin and other related antibiotics. Due to the known ototoxic and nephrotoxic potential of neomycin sulphate the use of NEOSPORIN ANTIBIOTIC POWDER in large quantities or on large areas for prolonged periods of time is not recommended in circumstances where significant systemic absorption may occur. A possibility of increased absorption exists in very young children, thus NEOSPORIN ANTIBIOTIC POWDER is not recommended for use in neonates and infants (less than 2 years). In neonates and infants, absorption by immature skin may be enhanced and renal function may be immature. The presence of pre-existing nerve deafness is a contraindication to the use of NEOSPORIN ANTIBIOTIC POWDER or any topical aminoglycoside in circumstances where significant systemic absorption could occur. NEOSPORIN ANTIBIOTIC POWDER should not be used to treat otitis externa in the presence of a perforated tympanic membrane because of the risk of ototoxicity. 2

Special Warnings And Special Precautions For Use As with other antibacterial preparations, prolonged use may result in the overgrowth of nonsusceptible organisms, including fungi. Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. Although this is unlikely to occur with topically applied antibiotics, if prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further. Following significant systemic absorption, aminoglycosides such as neomycin can cause irreversible ototoxicity; neomycin sulphate, polymyxin B sulphate and bacitracin zinc have nephrotoxic potential and polymyxin B sulphate has neurotoxic potential. In renal impairment the plasma clearance of neomycin is reduced (see Posology and Method of Administration). The concurrent use of other aminoglycoside antibiotics is not recommended in circumstances where significant systemic absorption of neomycin sulphate could occur following topical application. Avoid introduction of NEOSPORIN ANTIBIOTIC POWDER into the eyes. If NEOSPORIN ANTIBIOTIC POWDER is accidentally introduced into the eye, the eye should be rinsed thoroughly with cold water. NEOSPORIN ANTIBIOTIC POWDER should be kept out of reach of children. Interaction with Other Medicaments and Other Forms of Interaction Following significant systemic absorption, both neomycin sulphate and polymyxin B sulphate can intensify and prolong the respiratory depressant effects of neuromuscular blocking agents. However, the neuromuscular blocking activity of neomycin sulphate and polymyxin B sulphate is unlikely to present a hazard during use of NEOSPORIN ANTIBIOTIC POWDER. Pregnancy and Lactation There is little information to demonstrate the possible effect of topically applied neomycin in pregnancy and lactation. However, neomycin present in maternal blood can cross the placenta and may give rise to a theoretical risk of foetal toxicity, thus use of NEOSPORIN ANTIBIOTIC POWDER is not recommended in pregnancy and lactation. 3

Effects on Ability to Drive and Use Machines None reported. Undesirable Effects The incidence of allergic hypersensitivity reactions to neomycin sulphate in the general population is low. There is, however, an increased incidence of hypersensitivity to neomycin in certain selected groups of patients in dermatological practice particularly those with venous stasis eczema and ulceration. Allergic hypersensitivity to neomycin sulphate following topical application may manifest itself as a reddening and scaling of the affected skin, as an eczematous exacerbation of the lesion or as a failure of the lesion to heal. Allergic hypersensitivity reactions following topical application of polymyxin B sulphate and bacitracin zinc are rare events but have been reported. Anaphylactic reactions following the topical administration of bacitracin zinc have been reported; but these are rare occurrences. Post marketing Data (with Neomycin-pomymyxin B- bacitracin skin ointment) Immune System Disorder Rare: Application site hypersensitivity General Disorders and Administration Site Conditions Rare: Application site reactions including pain, erythema, oedema, pruritis and exacerbation of underlying skin conditions. Overdose Symptoms and Signs Following accidental ingestion of NEOSPORIN ANTIBIOTIC POWDER, minimal absorption is expected. No specific symptoms or signs have been associated with excessive use of NEOSPORIN ANTIBIOTIC POWDER. However, consideration should be given to significant systemic absorption (see Special Warnings and Special Precautions for Use). Treatment Use of the product should be stopped and the patient s general status, hearing acuity, renal and neuromuscular functions should be monitored. 4

Blood levels of neomycin sulphate, polymyxin B sulphate and bacitracin zinc should also be determined, and haemodialysis may reduce the serum level of neomycin sulphate. PHARMACOLOGICAL PROPERTIES Pharmacodynamic Properties Mechanism of action Polymyxin B sulphate : Polymyxin B is thought to damage the bacterial cytoplasmic membrane, which subsequently causes leakage of the intracellular components. The drug interferes with the structure and function of outer and cytoplasmic membranes in gram-negative bacteria. The polymyxins interact with lipopolysaccharides and phospholipids of the outer membrane. They also interact electrostatically by displacing calcium and magnesium from negatively charged phosphate groups of membrane lipids. Neomycin sulphate : Neomycin is an aminoglycoside antibiotic which acts by binding to a specific protein on the 30S subunit of the microbial ribosome, leading to faulty alignment or recognition with respect to messenger RNA and probably t-rna during initiation of microbial peptide chain formation. The messenger RNA is misread on the recognition region of the ribosome, resulting in the wrong amino acid being inserted into the peptide. The affected ribosomes are released and may be able to re-initiate and repeat the process, leading to increased proportions of nonfunctional peptide chains. Bacitracin Zinc: Bacitracin is a mixture of polypeptides derived from Bacillus subtilis. It inhibits growth of bacteria primarily by preventing the formation of peptidoglycan chains needed for cell wall synthesis and by altering membrane permeability Pharmacodynamic Effects NEOSPORIN ANTIBIOTIC POWDER is active in vitro against a wide range of bacterial pathogens found in superficial dermatological infections. Susceptible organisms include: Gram-positive: - Staphylococcus spp. including Staphylococcus aureus - Streptococcus spp. including Streptococcus pyogenes. Gram-negative: - Enterobacter spp. - Escherichia spp. - Haemophilus spp. - Klebsiella spp. - Neisseria spp. - Proteus spp. - Pseudomonas spp. including Pseudomonas aeruginosa. 5

Pharmacokinetic Properties Neomycin sulphate : Absorption through skin is limited. Topical application of neomycin in petrolatum does not result in detectable drug concentrations in either serum or urine. Preclinical Safety Data No relevant data. PHARMACEUTICAL PARTICULARS List of Excipients Starch (Sanitised), Polysan [Idophor with Tamed Iodine (Iodine 1.6% w/v containing Alkyl phenoxy polyethoxy Ethanol in water)} Incompatibilities No incompatibilities have been identified. Shelf-Life 24 months. The expiry date is indicated on the label and packaging. Special Precautions for Storage Store in a cool dry place. Keep out of reach of children. Nature and Specification of Container HDPE bottle. Instructions for Use / Handling FOR EXTERNAL USE ONLY. Keep container tightly closed. 6

For further information please contact: GlaxoSmithKline Pharmaceuticals Limited Registered Office Dr. Annie Besant Road, Worli, Mumbai 400 030, India. NEOSPORIN is a Registered Trademark of the GSK group of companies. Version: NEO-POW/PI/IN/2016/01 dated 31 December 2016. Adapetd from Neomycin-polymyxin B- bacitracin topical and opthalmic ointment GDS Version 09 dated 13 September 2012. 7